

PCTWORLD INTELLECTUAL
PROPERTY ORGANIZATION

WO 9604901A1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ :

A61K 31/19

A1

(11) International Publication Number:

WO 96/04901

(43) International Publication Date:

22 February 1996 (22.02.96)

(21) International Application Number: PCT/US95/10318

(22) International Filing Date: 14 August 1995 (14.08.95)

(30) Priority Data:

08/289,957	12 August 1994 (12.08.94)	US
08/337,349	10 November 1994 (10.11.94)	US
08/496,710	29 June 1995 (29.06.95)	US

(71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors: HELTON, David, Reed; 2607 South Bo-Mar Lane, Greenfield, IN 46140 (US). KALLMAN, Mary, Jeanne; 1569 East 300 North, Greenfield, IN 46140 (US). MONN, James, Allen; 7518 Allenwood Court, Indianapolis, IN 46268 (US). SCHOEPP, Darryle, Darwin; 7722 Warbler Way, Indianapolis, IN 46143 (US). TIZZANO, Joseph, Patrick; 6682 West Sweet Creek Drive, New Palestine, IN 46163 (US).

(74) Agent: LAMMERT, Steven, R.; Barnes & Thornburg, 1313 Merchants Bank Building, 11 South Meridian Street, Indianapolis, IN 46204 (US).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published

With international search report.

(54) Title: COMPOSITION AND METHOD FOR TREATING ANXIETY

(57) Abstract

The present invention provides the use of an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors for the treatment of anxiety and related disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

COMPOSITION AND METHOD FOR TREATING ANXIETY

The present invention relates to the treatment of anxiety and related disorders.

5 The fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV™), published in 1994 by the American Psychiatric Association, Washington, DC, defines anxiety and related disorders. These are panic disorder without agoraphobia, panic disorder with agoraphobia,
10 agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder, generalized anxiety disorder, anxiety disorder due to a general medical condition, substance-induced anxiety disorder and anxiety
15 disorder not otherwise specified.

Anxiety disorders are generally treated by counseling or with drugs. Classes of drugs which are widely prescribed for the treatment of anxiety disorders include the benzodiazepines (such as diazepam) and buspirone
20 hydrochloride.

The benzodiazepines were introduced during the 1960's. They have achieved widespread acceptance, but their use is nevertheless restricted due to their adverse side-effect profile, in particular their tendency to induce dependence.

25 Buspirone hydrochloride was introduced during the early 1980's. It lacks the dependence-inducing side effects of the benzodiazepines, but has a slow onset of action (about 4 weeks).

There is therefore a need for new drugs for the
30 treatment of anxiety and related disorders.

Several animal models have been developed which are recognized in the art as being predictive of anxiolytic activity. These include the fear potentiated startle model, described by Davis in Psychopharmacology 62:1;
35 1979 and Behav. Neurosci. 100:814;1986, the elevated plus model described by Lister in Psychopharmacol. 92:180-185;1987, and the well-known punished -

responding (conflict) model, described, for example, in "Psychopharmacology of Anxiolytics and Antidepressants", edited by S.E. File, pp. 131-153, Raven Press, New York, 1991.

5 In the mammalian central nervous system (CNS), the transmission of nerve impulses is controlled by the interaction between a neurotransmitter, that is released by a sending neuron, and a surface receptor on a receiving neuron, causing excitation of this receiving
10 neuron. The benzodiazepines and buspirone hydrochloride are both believed to exert their anxiolytic effect through binding to such receptors. In particular, the benzodiazepines are believed to act by binding to GABA receptors, while buspirone hydrochloride is believed to
15 bind to 5HT_{1a} receptors.

L-Glutamate, which is the most abundant neurotransmitter in the CNS, mediates the major excitatory pathway in mammals, and is referred to as an excitatory amino acid (EAA). The receptors that respond
20 to glutamate are called excitatory amino acid receptors (EAA receptors). See Watkins & Evans, *Ann. Rev. Pharmacol. Toxicol.*, **21**, 165 (1981); Monaghan, Bridges, and Cotman, *Ann. Rev. Pharmacol. Toxicol.*, **29**, 365 (1989); Watkins, Krogsgaard-Larsen, and Honore, *Trans. Pharm. Sci.*, **11**, 25 (1990). The excitatory amino acids
25 are of great physiological importance, playing a role in a variety of physiological processes, such as long-term potentiation (learning and memory), the development of synaptic plasticity, motor control, respiration,
30 cardiovascular regulation, emotional states and sensory perception.

Excitatory amino acid receptors are classified into two general types. Receptors that are directly coupled to the opening of cation channels in the cell membrane
35 of the neurons are termed "ionotropic." This type of receptor has been subdivided into at least three subtypes, which are defined by the depolarizing actions

of the selective agonists *N*-methyl-D-aspartate (NMDA), α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), and kainic acid (KA). The second general type of receptor is the G-protein or second messenger-linked "metabotropic" excitatory amino acid receptor. This second type is coupled to multiple second messenger systems that lead to enhanced phosphoinositide hydrolysis, activation of phospholipase D, increases or decreases in cAMP formation, and changes in ion channel function. Schoepp and Conn, *Trends in Pharmacol. Sci.*, **14**, 13 (1993). Both types of receptors appear not only to mediate normal synaptic transmission along excitatory pathways, but also participate in the modification of synaptic connections during development and throughout life. Schoepp, Bockaert, and Sladeczek, *Trends in Pharmacol. Sci.*, **11**, 508 (1990); McDonald and Johnson, *Brain Research Reviews*, **15**, 41 (1990).

The metabotropic glutamate receptors are a highly heterogeneous family of glutamate receptors that are linked to multiple second-messenger pathways. Generally, these receptors function to modulate the presynaptic release of glutamate, and the postsynaptic sensitivity of the neuronal cell to glutamate excitation. The metabotropic glutamate receptors (mGluR) have been pharmacologically divided into two subtypes. One group of receptors is positively coupled to phospholipase C, which causes hydrolysis of cellular phosphoinositides (PI). This first group are termed PI-linked metabotropic glutamate receptors. The second group of receptors is negatively coupled to adenylyl cyclase, which prevents the forskolin-stimulated accumulation of cyclic adenosine monophosphate (cAMP). Schoepp and Conn, *Trends Pharmacol. Sci.*, **14**, 13 (1993). Receptors within this second group are termed cAMP-linked metabotropic glutamate receptors.

It has now been found that a compound which is an agonist that acts selectively at negatively coupled cAMP-linked metabotropic glutamate receptors is effective in the

fear potentiated startle and elevated plus maze models of anxiety (but does not have benzodiazepine-like efficacy in the punished-responding (conflict) model).

The present invention provides the use of an agonist
5 which acts at negatively coupled cAMP-linked metabotropic glutamate receptors for the treatment of anxiety and related disorders.

It has been found that a novel compound which acts selectively as an agonist at negatively coupled cAMP-linked
10 metabotropic glutamate receptors, (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid is effective in the fear potentiated startle and elevated plus maze models of anxiety. Since the benzodiazepines and buspirone hydrochloride are effective in these models and are useful
15 generally in the treatment of anxiety disorders, it is believed that anxiety disorders will be treatable using any agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors, especially an agonist which acts selectively.

20 The fear potentiated startle and elevated plus models both measure the ability of a test compound to protect a test animal from the effect of exposure to an anxiety-producing environment. In the former test, the anxiety-producing environment comprises a neutral stimulus, such as a light,
25 which the test animal has been conditioned to associate with an adverse stimulus, such as an electric shock. In the latter test, the anxiety-producing environment comprises an open space, for which rodents have a natural aversion.

According to a preferred aspect, therefore, the present
30 invention provides the use of an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors for protecting a mammal from the effect of an anxiety-producing environment, preferably an agonist which acts selectively.

35 It will be appreciated that the effect of an anxiety producing environment on a mammal may be conditioned (as measured in the fear potentiated startle model) or natural

(as measured in the elevated plus maze model). Accordingly, a particular environment may produce anxiety in only specific individuals or in a general population.

5 Examples of anxiety disorders which can be produced in specific individuals are those described in the Diagnostic and Statistical Manual of Mental Disorders, published in 1994 by the American Psychiatric Association, Washington, D.C.

10 The particular dose of agonist administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the activity of the particular agonist administered, the route of administration, the particular condition being treated, and similar considerations. The agonist can be administered by a
15 variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, or intranasal routes. Alternatively, the agonist may be administered by continuous infusion. A typical daily dose will contain from about 0.001 mg/kg to about 100 mg/kg of the
20 agonist. Preferably, daily doses will be about 0.05 mg/kg to about 50 mg/kg, more preferably from about 0.1 mg/kg to about 20 mg/kg.

Agonists which act at negatively coupled cAMP-linked metabotropic glutamate receptors may be
25 identified using the following experiment. Firstly, the affinity of a test compound for metabotropic glutamate receptors may be demonstrated by the selective displacement of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-sensitive [³H]glutamate binding to rat
30 brain cell membranes. The binding of [³H]glutamate ([³H]Glu) is conducted with crude membranes of rat forebrain as described by Schoepp and True. Schoepp and True, *Neuroscience Lett.*, **145**, 100-104 (1992); Wright, McDonald, and Schoepp, *J. Neurochem.*, **63**, 938-945
35 (1994). The affinity of a test compound for the receptor may be expressed as the concentration of the test compound that inhibits 50% binding (IC₅₀), or the

percent displacement of [^3H]Glu at a 10 μM or 100 μM concentration of the formula I compound. In this test, the IC_{50} for (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid was found to be 0.18 μM .

5 The ability of a test compound to act as an agonist at negatively coupled cAMP-linked metabotropic receptors may be measured using the following method. Test compounds are tested for their ability to decrease forskolin-stimulated cAMP formation in the rat
10 hippocampus and the rat cerebral cortex, using the procedures described in Schoepp and Johnson. Schoepp and Johnson, *Neurochem. Int.*, **22**, 277-283 (1993). In this test, (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid was found to give the result shown in
15 Table II below.

**Table II. Inhibition of Forskolin-Stimulated
cAMP Formation**

20		EC_{50} (μM)
	Rat cerebral cortex	$.055 \pm .017$
	Rat hippocampus	$.036 \pm .015$

25 The ability of formula I compounds to treat anxiety or a related disorder may be demonstrated using the well known fear potentiated startle and elevated plus maze models of anxiety.

 In the fear potentiated startle model, animals are
30 exposed to a neutral stimulus such as light (conditioned stimulus) with an aversive stimulus such as a shock (unconditioned stimulus). Following conditioning, when the animals are presented with a loud acoustic stimulus, larger startle responses are elicited when the startle
35 stimulus is preceded by light.

 The elevated plus maze model is based upon the natural aversion of rodents to height and open spaces.

Diazepam and buspirone hydrochloride, which are clinically proven anxiolytics, are effective at reducing the fear (increased startle response) associated with the presentation of light in the fear potentiated startle model, and in reducing the fear of open spaces in the elevated plus maze model.

Male Long Evans rats (180-400 g) or male NIH Swiss mice (18-35 g) were obtained from Harlan Sprague-Dawley, Cumberland, IN, USA and acclimated at least 3 days before testing. Animals were housed at $23 \pm 2^\circ\text{C}$ (relative humidity 30% to 70%) and given Purina Certified Rodent Chow and water ad libitum. The photoperiod was 12 hours of light and 12 hours of dark, with dark onset at approximately 1800 hours.

Test compounds were dissolved in a vehicle of purified water and neutralized with 5 N NaOH to a pH of 7-8 when applicable. Diazepam (Sigma Chemical Company, St. Louis, MO) was suspended in purified water by the dropwise addition of Tween 80. Control animals received the respective vehicle.

Fear Potentiated Startle: SL-LAB (San Diego Instruments, San Diego, CA) chambers were used for conditioning sessions and for the production and recording of startle responses. A classical conditioning procedure was used to produce potentiation of startle responses. Briefly, on the first 2 days, rats were placed into dark startle chambers in which shock grids were installed. Following a 5-minute acclimation period, each rat received a 1mA electric shock (500ms) preceded by a 5 second presentation of light (15 watt) which remained on for the duration of the shock. Ten presentations of the light and shock were given in each conditioning session, rats were gavaged with a solution of test compound of water and startle testing sessions were conducted. A block of 10 consecutive presentations of acoustic startle stimuli (110 dB, non-light-paired) were presented at the

beginning of the session in order to minimize the influences of the initial rapid phase of habituation to the stimulus. This was followed by 20 alternating trials of the noise alone or noise preceded by the light. Excluding the initial trial block, startle response amplitudes for each trial type (noise-alone vs. light+noise) were averaged for each rat across the entire test session. Data are presented as the difference between noise-alone and light+noise. (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid was found to give an ED₅₀ of 0.3 mg/kg, p.o. in this test.

Automated Elevated Plus Maze: Construction of the elevated plus-maze was based on a design validated for mice by Lister (1987). The entire maze was made of clear Plexiglas. The maze was comprised of two open arms (30x5x0.25 cm) and two enclosed arms (30x5x15 cm). The floor of each maze arm was corrugated to provide texture. The arms extended from a central platform and angled at 90 degrees from each other. The maze was elevated to a height of 45 cm above the floor and illuminated by red light. Individual infrared photocells were mounted along each arm of the maze to monitor closed, open, or nosepoke activity. Mice were individually placed on the central platform of the maze and the number of closed arm, open arm, and nosepoke (poking head only into open arm from closed arm of maze) counts were recorded and used as a measure of arm entries and time spent on various sections of the maze over a five-minute test period.

Oral administration of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid produced significant increases in open arm activity at doses of 1, 3 and 10 mg/kg. Nosepoke counts showed a significant increase at 3mg/kg. Closed arm activity counts were not significantly altered at any dose of the compound.

(+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid may be prepared by reacting carbethoxymethyl

dimethylsulfonium bromide with 2-cyclopenten-1-one in the presence of a base, such as 1,8-diazabicyclo[5.4.0]undec-7-ene to afford ethyl 2-oxobicyclo[3.1.0]hexane-6-carboxylate. This ester may then be reacted with an aqueous solution of potassium cyanide or sodium cyanide and ammonium carbonate to produce an intermediate hydantoin, (the Bucherer-Bergs reaction), which is then hydrolysed using sodium hydroxide, to afford a diastereomeric mixture of diethyl 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. The desired diastereomer may be obtained by crystallization with oxalic acid. This diastereomer may then be resolved by forming a crystalline salt with (+)-di-p-toluoyl-D-tartaric acid and recovering (-)-diethyl 2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate. Hydrolysis of this diester using aqueous sodium hydroxide gives (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid. Alternatively, the ethyl 2-oxobicyclo[3.1.0]hexane-6-carboxylic acid may be hydrolysed using sodium hydroxide to give 2-oxobicyclo[3.1.0]hexane-6-carboxylic acid. This acid may then be resolved by forming a crystalline salt with (S)-1-phenylethylamine and recovering (+)-2-oxobicyclo[3.1.0]hexane-6-carboxylic acid. This acid may then be converted into (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid by reaction with an aqueous solution of potassium cyanide or sodium cyanide and ammonium carbonate to produce an intermediate hydantoin (the Bucherer-Bergs reaction) followed by hydrolysis of the hydantoin using sodium hydroxide. This procedure may also be modified by performing the resolution step on the hydantoin rather than on the 2-oxobicyclo[3.1.0]hexane-6-carboxylic acid. In this case, (R)-1-phenylethylamine has been found to be a suitable resolving agent.

The agonists are preferably formulated prior to administration in combination with one or more pharmaceutically-acceptable carriers, diluents, or

excipients. The pharmaceutical formulations are prepared by known procedures using well-known and readily available ingredients. In making the compositions, the active ingredient will usually be
5 mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may be in the form of a capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle,
10 excipient, or medium for the active ingredient. The compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments containing, for example, up to 10% by weight
15 of active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, dermal patch, subcutaneous implant, and sterile packaged powders.

Some examples of suitable carriers, excipients, and
20 diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and
25 propyl hydroxybenzoates, talc, magnesium stearate, stearic acid, and mineral oil. The formulations can additionally include lubricating agents, wetting agents (surfactants), emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring
30 agents. Compositions may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

The compositions are preferably formulated in a
35 unit dosage form, each dosage containing from about 1 mg to about 500 mg, more preferably about 5 mg to about 200 mg of the active ingredient. The term "unit dosage

form" refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient. The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way.

Formulation 1

5 Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
10 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid	250
15 Starch, dried	200
Magnesium stearate	<u>10</u>
Total	460 mg

20 The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.

Formulation 2

25 A tablet is prepared using the ingredients below:

	Quantity (mg/tablet)
30 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid	250
35 Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	<u>5</u>
Total	665 mg

40 The components are blended and compressed to form tablets each weighing 665 mg.

Formulation 3

An aerosol solution is prepared containing the following components:

	Weight %
2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid	0.25
Ethanol	29.75
Propellant 22	<u>70.00</u>
(chlorodifluoromethane)	
Total	100.00

The active compound is mixed with ethanol and the mixture added to a portion of the Propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

Formulation 4

Tablets each containing 60 mg of active ingredient are made as follows:

2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid	60 mg
Starch	45 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	<u>1 mg</u>
Total	150 mg

14

The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Formulation 5

Capsules each containing 80 mg of active ingredient are made as follows:

2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid	80 mg
Starch	59 mg
Microcrystalline cellulose	59 mg
Magnesium stearate	<u>2 mg</u>
Total	200 mg

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 sieve, and filled into hard gelatin capsules in 200 mg quantities.

Formulation 6

Suppositories each containing 225 mg of active ingredient may be made as follows:

2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid	225 mg
Saturated fatty acid glycerides	<u>2,000 mg</u>
Total	2,225 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

Formulation 7

Suspensions each containing 50 mg of active ingredient per 5 ml dose are made as follows:

2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 ml
Benzoic acid solution	0.10 ml
Flavor	q.v.
Color	q.v.
Purified water to total	5 ml

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.

Formulation 8

An intravenous formulation may be prepared as follows:

2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid	100 mg
Mannitol	100 mg
5 N Sodium hydroxide	200 ml
Purified water to total	5 ml

The following Examples further illustrate methods for their synthesis of (+)-2-aminobicyclo[3.1.0]hexane-

2,6-dicarboxylic acid. The Examples are not intended to be limiting to the scope of the invention in any respect, and should not be so construed. All experiments were run under a positive pressure of dry nitrogen or argon. All solvents and reagents were purchased from commercial sources and used as received, unless otherwise indicated. Dry tetrahydrofuran (THF) was obtained by distillation from sodium or sodium benzophenone ketyl prior to use. Proton nuclear magnetic resonance (^1H NMR) spectra were obtained on a GE QE-300 spectrometer at 300.15 MHz, a Bruker AM-500 spectrometer at 500 MHz, or a Bruker AC-200P spectrometer at 200 MHz. Free atom bombardment mass spectroscopy (FABMS) was performed on a VG ZAB-2SE instrument. Field desorption mass spectroscopy (FDMS) was performed using either a VG 70SE or a Varian MAT 731 instrument. Optical rotations were measured with a Perkin-Elmer 241 polarimeter. Chromatographic separation on a Waters Prep 500 LC was generally carried out using a linear gradient of the solvents indicated in the text. The reactions were generally monitored for completion using thin layer chromatography (TLC). Thin layer chromatography was performed using E. Merck Kieselgel 60 F254 plates, 5 cm X 10 cm, 0.25 mm thickness. Spots were detected using a combination of UV and chemical detection (plates dipped in a ceric ammonium molybdate solution [75 g of ammonium molybdate and 4 g of cerium (IV) sulfate in 500 mL of 10% aqueous sulfuric acid] and then heated on a hot plate). Flash chromatography was performed as described by Still, et al. Still, Kahn, and Mitra, *J. Org. Chem.*, **43**, 2923 (1978). Elemental analyses for carbon, hydrogen, and nitrogen were determined on a Control Equipment Corporation 440 Elemental Analyzer, or were performed by the Universidad Complutense Analytical Centre (Facultad de Farmacia, Madrid, Spain). Melting points were determined in open glass capillaries on a Gallenkamp hot

air bath melting point apparatus or a Büchi melting point apparatus, and are uncorrected. The number in parenthesis after the compound name refers to the compound number.

5

Preparation 1

Carbethoxymethyl Dimethylsulfonium Bromide

10 A solution of ethyl bromoacetate (265g) and dimethyl sulfide (114g) in acetone (500mL) was stirred at room temperature. After three days, the title compound was isolated by filtration of the reaction mixture. Melting point 88-90°C.

15

Example 1

(1SR,5RS,6SR) Ethyl 2-Oxobicyclo[3.1.0]hexane-6-carboxylate

20 A suspension of carbethoxymethyl diethylsulfonium bromide (45.5g) in toluene (350mL) was treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (30.2g). The resulting mixture was stirred at room temperature. After one hour, the reaction mixture was treated with 2-cyclopenten-1-one (19.57g). After an additional 18
25 hours, the reaction mixture was added to a 1 N hydrochloric acid/sodium chloride solution. The resulting mixture was extracted with diethyl ether. The combined ether extracts were dried over magnesium sulfate, filtered, and concentrated *in vacuo*. The
30 residue was purified using silica-gel chromatography, eluting with a linear gradient of 10% ethyl acetate/hexanes to 50% ethyl acetate/hexanes, to give 22.81g of the title compound. Melting point: 36-38°C.

35 FDMS: $m/z = 168$ (M^+).

Analysis calculated for $C_9H_{12}O_3$: C, 64.27; H, 7.19.

Found: C, 64.54; H, 7.11.

Example 2

(1SR,2RS,5RS,6SR) Diethyl 2-Aminobicyclo[3.1.0]-
hexane-2,6-dicarboxylate and

5 (1SR,2SR,5RS,6SR) Diethyl 2-Aminobicyclo[3.1.0]-
hexane-2,6-dicarboxylate

A solution of the compound prepared as described in
Example 1 (22.81g) in ethanol (200mL) was treated with
10 an aqueous solution of potassium cyanide (9.71g) and
ammonium carbonate (21.2g) in water (200mL). The
resulting mixture was heated to about 50°C. After about
18 hours, the reaction mixture was allowed to cool to
room temperature and treated with sodium hydroxide
15 (16.2g). The resulting mixture was heated to reflux.
After about 18 hours, the reaction mixture was allowed
to cool to room temperature, then cooled to 0°C. The pH
of the cold mixture was adjusted to pH 1 by the addition
of concentrated hydrochloric acid. This mixture was
20 concentrated to dryness *in vacuo*. The residue was
dissolved in ethanol, cooled to 0°C, and treated with
thionyl chloride (80.6g). The resulting mixture was
heated to reflux. After about 48 hours, the reaction
was concentrated to dryness *in vacuo*. The residue was
25 treated with 1 N sodium hydroxide, and the resulting
mixture extracted with diethyl ether. The combined
ether extracts were dried over potassium carbonate,
filtered, and concentrated *in vacuo* to give 24.6g of a
mixture of the title compounds.

30

Example 3

(1SR,2SR,5RS,6SR) Diethyl 2-Aminobicyclo[3.1.0]-
hexane-2,6-dicarboxylate

35 A solution of the compounds prepared as described
in Example 2 (20.71g) in ethyl acetate (200mL) was
treated with a solution of oxalic acid (15.46g) in

19

ethanol (50mL). The resulting mixture was stirred at room temperature. After one hour, the reaction mixture was treated with additional ethanol (50mL). After 18 hours, the mixture was filtered, and the filtrate was
5 evaporated to dryness *in vacuo*. The residue was treated with 1 N sodium hydroxide, and the resulting mixture extracted with diethyl ether. The combined ether extracts were washed with brine, dried over potassium carbonate, filtered, and concentrated *in vacuo*. The
10 residue was purified by silica-gel chromatography, eluting with methylene chloride:5% ammonium hydroxide/methanol (97:3), to give 15.41g of the title compound.

15 FDMS: $m/z = 242$ (M+H).
Analysis calculated for $C_{12}H_{19}NO_4$: C, 59.74; H, 7.94; N, 5.81. Found: C, 59.78; H, 8.13; N, 5.77.

Example 4

20 (-)-Diethyl 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate

A solution of the racemic mixture of compounds prepared as described in Example 3 (6.56g) in ethyl
25 acetate (100mL) was treated with a solution of (+)-di-p-toluoyl-D-tartaric acid (12.0g) in ethyl acetate (100mL). After standing overnight at room temperature, the crystalline solid was removed by filtration and dried to give 14.7g. Additional crystalline solid was
30 obtained by cooling the filtrate to 0°C. The combined crystalline solids were dissolved in hot ethyl acetate, containing enough 2-propanol for complete dissolution. After cooling to 0°C, the crystalline solid was isolated by filtration, to give 2.3g of a solid having an
35 enantiomeric excess of $\geq 95\%$. The freebase form was obtained by partitioning the salt between aqueous sodium bicarbonate and ethyl acetate. The organic phase was

separated, dried over potassium carbonate, filtered, and concentrated *in vacuo* to give .77g of the title compound.

- 5 FDMS: $m/z = 242$ (M+H).
Optical rotation: $\alpha_D = -5.15'$ ($c = 1$, EtOH).
Analysis calculated for $C_{12}H_{19}NO_4$: C, 59.74; H, 7.94; N, 5.81. Found: C, 59.68; H, 8.13; N, 5.58.

10

Example 5

(+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid

- A solution of the compound prepared as described in Example 4 (0.69g) in tetrahydrofuran (10mL) was treated
15 with 1 N sodium hydroxide (10mL), and the resulting mixture vigorously stirred at room temperature. After several days, the title compound was isolated by anion-exchange chromatography (Bio-Rad AG1-X8), eluting with 50% acetic acid/water, to give 0.53g of the title
20 compound.

- FDMS: $m/z = 186$ (M+H).
Optical rotation: $\alpha_D = 21.32'$ ($c = 1$, 1 N HCl).
Analysis calculated for $C_8H_{11}NO_4 \cdot 1.25H_2O$: C, 46.26; H, 6.55; N, 6.74. Found: C, 46.68; H, 6.47; N, 6.49.
25

Example 6

2-Oxobicyclo[3.1.0]hexane-6-carboxylic acid

30

- A mixture of 60 g of (1SR,5RS,6SR) ethyl 2-oxobicyclo[3.1.0]hexane-6-carboxylate and 300 ml of 1 N sodium hydroxide was stirred at 25-30°C. After 2.5 hours, concentrated hydrochloric acid was added to adjust the pH to 0.8-1.2. The
35 resulting solution was extracted with ethyl acetate. The extracts were dried over magnesium sulfate, filtered, and concentrated to give 49.1 g (98%) of the crude material.

21

Recrystallization from 100 ml of ethyl acetate gave the title compound, mp 123.5-128°C.

FDMS: $m/z = 140$ (M^+)

5 Analysis calculated for $C_7H_8O_3$: C, 60.00; H, 5.75. Found: C, 60.14; H, 5.79.

Example 7

10 2-Oxobicyclo[3.1.0]hexane-6-carboxylic acid salt with (S)-1-phenylethylamine

A solution of 14 g of the compound prepared in Example 6 in 140 ml of 25% ethanol in ethyl acetate was combined with (S)-
15 1-phenylethylamine (1 eq.). After stirring overnight, the precipitated salt was isolated by filtration and dried to give 11.87 g (45.4%) of the desired salt. Conversion of the salt to the partially resolved 2-oxobicyclo[3.1.0]hexane-6-carboxylic acid by the method of Example 8 and analysis
20 indicated that the salt was 68% ee. The enantiomeric excess was determined by conversion to the methyl ester with diazomethane followed by chiral HPLC on a Chiralpak AS column at 40°C eluted with 10% isopropanol/90% hexane at 1 ml/min with detection at 210 nm.

25

Example 8

(+)-2-Oxobicyclo[3.1.0]hexane-6-carboxylic acid

30 A mixture of 1.31 g of the product of Example 7 and 10 ml of 1N hydrochloric acid was stirred for 5 minutes and extracted with ethyl acetate. The extracts were dried over sodium sulfate, filtered, and concentrated to give 0.61 g of the title compound, mp 110-115°C. The product was determined to
35 be 68% ee by chiral HPLC (method of Example 7).

FDMS: $m/z = 141$ ($M+H$)

Optical Rotation: $\alpha_D = 49.85^\circ$

40

Example 9

(-)-2-Spiro-5'-hydantoinbicyclo[3.1.0]hexane-6-carboxylic acid

5

A solution of the compound prepared as described in Example 8 (68% ee, 1 eq.), potassium cyanide (1.25 eq.), and ammonium carbonate (2.5 eq) were combined and stirred in ethanol/water at 25°C for 40 hours. The mixture was acidified with 6N hydrochloric acid, concentrated, diluted with water, and filtered to give a 79% yield of a 90:10 mixture of diastereomers, mp 286-290°C. The diastereomeric mixture was recrystallized from isopropanol/water to give in 48% yield the title compound in 100% diastereomeric and 100% enantiomeric purity (enantiomeric ratio determined by chiral HPLC on a 4.6 x 150 mm Chiralcel OD-H column, eluted with 15 % isopropanol/85% hexane at 1 ml/min at 40°C with detection at 220 nm; diastereomeric ration determined by HPLC on a Zorbax SB-phenyl column at 40°C with elution with 90:10 buffer/acetonitrile eluted at 2 ml/min with detection at 220 nm (buffer = 0.1 M dibasic sodium phosphate monohydrate adjusted to pH 2.1 with phosphoric acid)).

25 FDMS: $m/z = 211$ (M + H)Optical Rotation: $\alpha_D = -25.98^\circ$

Analysis calculated for C₉H₁₀N₂O₄: C, 51.43; H, 4.79; N, 13.33. Found: C, 51.38; H, 4.80; N, 13.26.

Example 10

30

Ethyl 2-spiro-5'-hydantoinbicyclo[3.1.0]hexane-6-carboxylate

A mixture of 5.05 g of ethyl 2-oxobicyclo[3.1.0]hexane-6-carboxylate, 2.15 g of potassium cyanide, 5.77 g of ammonium carbonate, 30 ml of 2B-3 ethanol, and 12 ml of water was stirred at 35°C until the reaction was complete by HPLC. After 15 hours, the reaction mixture was cooled to 0°C and 33 ml of water was added to the mixture. After 2 hours at 0°C,

23

the precipitate was isolated by filtration and dried to give 5.23 g (73%) of the title compound, mp 217-220°C.

FDMS: $m/z = 238.1$ (M+)

5 Analytical calculated for $C_{11}H_{14}N_2O_4$: C, 55.46; H, 5.92; N, 11.76. Found: C, 55.74; H, 5.88; N, 11.50.

Example 11

10 2-Spiro-5'-hydantoinbicyclo[3.1.0]hexane-6-carboxylic acid

A mixture of 16.32 g of the product of Example 10 and 137 ml of 2N NaOH was stirred at 25°C. After 1 hour, concentrated hydrochloric acid was added to adjust the pH to 1.0. The
15 resulting precipitate was isolated by filtration and dried to give 13.70 g (95%) of the title compound, mp 277-279°C.

FDMS: $m/z = 210.1$ (M+)

Analysis Calculated for $C_9H_{10}N_2O_4$: C, 51.43; H, 4.79; N, 13.33. Found: C, 51.70; H, 4.93; N, 13.43.
20

Example 12

25 2-Spiro-5'-hydantoinbicyclo[3.1.0]hexane-6-carboxylic acid,
(S)-1-phenylethylamine salt

A mixture of 1.05 g of the product of Example 11 and 16.6 ml of a 1.6 : 1 solution of acetone : water was stirred at 25°C while adding 1.53 g of R-(+)-1-phenylethylamine. The mixture
30 was stirred for 2 hours at room temperature. The crystals were filtered, rinsed with acetone, and dried to give 0.74 g (45%) of the title compound, mp 205-212°C.

Optical Rotation: $\alpha_D = -31.88^\circ$ (c = 1, methanol)

Example 13

(-)-2-Spiro-5'-hydantoinbicyclo[3.1.0]hexane-6-carboxylic
5 acid

A mixture of 0.74 g of the product of Example 12 and 10 ml of water was stirred at 25°C while the pH was adjusted from 6.81 to 1.0 using 1N HCl. The reaction mixture was stirred for 1
10 hour and the product was collected by filtration and dried to give 0.35 g (75%) of the title compound, mp 310°C (decomp).

FDMS: 210.1 (M+)

Optical Rotation: $\alpha_D = -24.22^\circ$ ($c = 1$, methanol)

15 Analysis calculated for $C_9H_{10}N_2O_4$: C, 51.43; H, 4.80;
N, 13.33. Found: C, 51.67; H, 4.87; N, 13.61.

Example 14

20 (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid

A solution of 184 g of (-)-2-spiro-5'-hydantoinbicyclo[3.1.0] hexane-6-carboxylic acid and 1750 ml of 3N NaOH was heated at reflux until the reaction was complete by HPLC. After 28 hours, the solution was cooled to room temperature and filtered through glass paper to remove trace amounts of insoluble material. The pH of the solution was adjusted to 3.0 using concentrated HCl. The reaction mixture was stirred 1 hour at room temperature and two hours at 0°C. The precipitated product was collected by filtration, washed with 170 ml of cold water and dried to give 152.5 grams (86%) of the title compound.

FDMS: $m/z = 186.1$ (M+1)

35 Optical rotation: $\alpha_D = 23.18^\circ$ (c = 1, 1N HCl)

Claims:

1. The use of an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors for the
5 manufacture of a medicament for the treatment of anxiety and related disorders.
2. Use as claimed in Claim 1, in which the agonist acts selectively.
10
3. The use of an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors for the manufacture of a medicament to provide protection from the effect of exposure to an anxiety-producing environment.
15
4. Use as claimed in Claim 3, in which the agonist acts selectively.
5. Use of an agonist which acts at negatively coupled cAMP-
20 linked metabotropic glutamate receptors for the treatment of anxiety and related disorder.
6. Use as claimed in Claim 5, in which the agonist acts selectively.
25
7. Use of an agonist which acts at negatively coupled cAMP-linked metabotropic glutamate receptors to provide protection from the effect of exposure to an anxiety-producing environment.
30
8. Use as claimed in Claim 7, in which the agonist acts selectively.
9. A pharmaceutical composition which comprises an agonist
35 that acts at negatively coupled cAMP-linked metabotropic glutamate receptors for use in the treatment of anxiety and related disorders.

26

10. A composition as claimed in Claim 9, in which the agonist acts selectively.

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/US95/10318

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/19

US CL :514/574

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/574

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/CAS

search terms: agonist, negatively coupled, camp-linked, metabotropic glutamate receptors, mglurs, anxiety

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Brain Research, Volume 629, issued 1993, M. Koch, "Microinjection of the Metabotropic Glutamate Receptor Agonist, Trans-($\pm$)-1-Amino-Cyclopentane-1,3-Dicarboxylate (Trans-ACPD) into the Amygdala Increase the Acoustic Startle Response of Rats", pages 176-179, see entire document.	1-10
Y	Neuropharmacology, Volume 32, No. 12, issued December 1993, Schoepp et al, "Metabotropic Glutamate Receptor Modulation of cAMP Accumulation in the Neonatal Rat Hippocampus", pages 1359-1365, see entire document.	1-10

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:		*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A	document defining the general state of the art which is not considered to be of particular relevance	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E	earlier document published on or after the international filing date	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G	document member of the same patent family
*O	document referring to an oral disclosure, use, exhibition or other means		
*P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

15 NOVEMBER 1995

Date of mailing of the international search report

05 DEC 1995

 Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ROSALYND A. WILLIAMS

Telephone No. (703) 308-1235